Barbara Kiesewetter
Medical University of Vienna
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Barbara Kiesewetter as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:10 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05868395 · Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell LymphomaMedical University of Vienna · recruiting · Mantle-cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:10 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.Clin Cancer Res · 201487 citationsRCR 3.5
- A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma).Haematologica · 201376 citationsRCR 2.3
- A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.Blood · 201749 citationsRCR 1.6
- 38 citationsRCR 1.3
- 31 citationsRCR 1.0
- Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.Br J Haematol · 201431 citationsRCR 1.0
- Treatment of mucosa associated lymphoid tissue lymphoma with a long-term once-weekly regimen of oral azithromycin: Results from the phase II MALT-A trial.Hematol Oncol · 201917 citationsRCR 0.8
- A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.Hematol Oncol · 20189 citationsRCR 0.3
- Is there a reliable size cut-off for splenic involvement in lymphoma? A [18F]FDG-PET controlled study.PLoS One · 20197 citationsRCR 0.3
- IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma.Haematologica · 20233 citationsRCR 0.3